Lamisil

Terbinafine Hydrochloride, the active ingredient in Lamisil, is an allylamine antifungal presented as an oral tablet for oral use. It treats dermatophyte skin infections such as athlete's foot and ringworm, as well as fungal nail infections in adult patients.

GNH USA supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamisil is an allylamine antifungal indicated for infections caused by dermatophyte fungi.

- Tinea pedis (athlete's foot): clears the infection and relieves itching and scaling. - Tinea corporis (ringworm): eliminates fungal growth and promotes normal skin healing. - Onychomycosis (fungal nail infection): eradicates nail fungus and improves nail appearance.

Adverse reactions may occur with oral terbinafine therapy.

Common Side Effects: - Gastrointestinal upset (nausea, abdominal pain) - Headache - Rash or mild skin irritation - Altered taste sensation - Elevated liver enzymes (asymptomatic)

Serious or Rare Side Effects: - Hepatotoxicity (clinical hepatitis, jaundice) - Severe cutaneous reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis) - Hematologic abnormalities (eosinophilia, neutropenia) - Anaphylactic or severe allergic reactions - Peripheral neuropathy

Before initiating therapy, consider the following precautions.

- Liver function monitoring: assess baseline hepatic enzymes and repeat if clinically indicated. - Hypersensitivity: avoid in patients with known allergy to terbinafine or other allylamines. - Concomitant hepatotoxic drugs: use with caution when combined with other agents that affect liver function. - Renal impairment: adjust therapy only under medical supervision. - Pediatric use: not recommended for children under 18 years without specialist advice. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Terbinafine may interact with several medicines; categorize as follows.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) – may increase terbinafine levels. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce efficacy.

Moderate Interactions (Monitor Closely): - Cimetidine – may raise terbinafine plasma concentrations. - Itraconazole or other azole antifungals – additive hepatotoxic risk. - Warfarin – monitor INR for possible increased anticoagulant effect. - Oral contraceptives – reduced effectiveness reported; consider alternative contraception. - Alcohol – may exacerbate liver enzyme elevations.